| Garden Park Health Care Center | |
| 3536 Washington Ave, Cincinnati, Ohio 45229 | |
| (513) 751-4900 | |
| Name | Garden Park Health Care Center |
|---|---|
| Location | 3536 Washington Ave, Cincinnati, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 87.5% |
| Medicare ID (CCN) | 365529 |
| Legal Business Name | Garden Park Health Care Center Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1316341191 |
| Organization Name | GARDEN PARK CC, INC. |
| Address | 3544 Washington Ave, Cincinnati, OH 45229 |
| Phone Number | 513-751-4900 |
News Archive
The Food and Drug Administration today has taken a critically important action to protect the American public from tobacco industry deception by warning several manufacturers – most prominently Reynolds American's subsidiary, Santa Fe Natural Tobacco Company, and its Natural American Spirit cigarette brand – that they are violating the law by marketing their products with health-related claims, including "additive-free" and "natural." If these products continue to make these claims, the FDA can and should order them removed from the market.
With major changes to Medicare likely on hold for the time being, advocates say the GOP has Medicaid "in its sights" as a more realistic place to make health care cuts.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
News outlets report that gubernatorial candidates in Florida and Minnesota are offering little details about their plans for health spending.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
› Verified 2 days ago
| NPI Number | 1477549400 |
| Organization Name | GARDEN PARK CC, INC. |
| Doing Business As | GARDEN PARK HEALTH CARE |
| Address | 3536 Washington Ave, Cincinnati, OH 45229 |
| Phone Number | 513-751-4900 |
News Archive
The Food and Drug Administration today has taken a critically important action to protect the American public from tobacco industry deception by warning several manufacturers – most prominently Reynolds American's subsidiary, Santa Fe Natural Tobacco Company, and its Natural American Spirit cigarette brand – that they are violating the law by marketing their products with health-related claims, including "additive-free" and "natural." If these products continue to make these claims, the FDA can and should order them removed from the market.
With major changes to Medicare likely on hold for the time being, advocates say the GOP has Medicaid "in its sights" as a more realistic place to make health care cuts.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
News outlets report that gubernatorial candidates in Florida and Minnesota are offering little details about their plans for health spending.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The Food and Drug Administration today has taken a critically important action to protect the American public from tobacco industry deception by warning several manufacturers – most prominently Reynolds American's subsidiary, Santa Fe Natural Tobacco Company, and its Natural American Spirit cigarette brand – that they are violating the law by marketing their products with health-related claims, including "additive-free" and "natural." If these products continue to make these claims, the FDA can and should order them removed from the market.
With major changes to Medicare likely on hold for the time being, advocates say the GOP has Medicaid "in its sights" as a more realistic place to make health care cuts.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
News outlets report that gubernatorial candidates in Florida and Minnesota are offering little details about their plans for health spending.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $12775 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.15 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 28.43 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 4.23 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 25.79 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.88 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 17.86 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.05 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 13.33 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.18 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 11.71 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 14.53 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |